medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 11, 2024
Abstract
The
ongoing
evolution
of
SARS-CoV-2,
particularly
through
the
emergence
new
variants,
continues
to
challenge
our
understanding
immune
protection.
While
antibody
levels
correlate
with
protection
against
earlier
variants
like
Alpha
and
Delta,
their
relationship
Omicron
sub-variants
remains
unclear.
To
investigate
role
neutralizing
activity
in
preventing
breakthrough
infections,
we
analyzed
longitudinal
SARS-CoV-2
humoral
responses
ancestral
virus
major
emerging
a
well-characterized
cohort
healthcare
workers
Spain
(N
=
405).
We
found
that
neutralization
titers
are
key
indicators
including
BQ.1
XBB
variants.
Higher
IgG
IgA
were
associated
over
three
6-month
follow-up
periods
sequentially
dominated
by
BA.1,
BA.2,
BA.5,
BQ.1,
sub-variants,
although
strength
association
between
declined
time.
Our
findings
demonstrate
binding
valid
more
evasive
this
Additionally,
results
underscore
importance
continuous
monitoring
updating
vaccination
strategies
maintain
effective
BMC Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: Aug. 20, 2024
According
to
Norwegian
registries,
91%
of
individuals
≥
16
years
had
received
1
dose
COVID-19
vaccine
by
mid-July
2022,
whereas
less
than
2%
children
<
12
were
vaccinated.
Confirmed
was
reported
for
27%
the
population,
but
relaxation
testing
lead
substantial
underreporting.
We
have
characterized
humoral
immunity
SARS-CoV-2
in
Norway
late
summer
2022
estimating
seroprevalence
and
identifying
antibody
profiles
based
on
reactivity
Wuhan
or
Omicron-like
viruses
a
nationwide
cross-sectional
collection
residual
sera,
validated
our
findings
using
cohort
sera.
Narra J,
Journal Year:
2024,
Volume and Issue:
4(2), P. e1071 - e1071
Published: Aug. 31, 2024
Due
to
the
persisting
development
of
SARS-CoV-2
variants,
studies
on
kinetics,
duration,
and
function
antibodies
are
essential
for
vaccine
long-term
immunity
prediction.
This
longitudinal
study
examined
post-vaccination
antibody
responses
in
people
after
receiving
CoronaVac
or
ChAdOx1
vaccines
with
without
a
history
infection.
Conducted
Indonesia
between
August
2021
May
2023,
this
involved
121
participants
divided
into
two
groups
based
received
types
monitored
18
months
post-second
dose
vaccination
by
assessing
binding
(BAb)
level
neutralizing
(NAb)
inhibition
rate
at
six
time
points.
The
also
documented
participants’
age,
gender,
body
mass
index
(BMI).
Before
first
vaccination,
85
(70.25%)
were
reactive
BAb
(defined
≥50
AU/mL)
indicating
In
group,
only
53.1%
BAb.
However,
100%
positive
NAb
≥30%),
which
indicates
past
infection
low
initial
rapidly
decreasing
levels.
81,9%
reactive,
while
54.2%
NAb,
suggesting
recent
high
but
relatively
rate.
During
levels
fluctuated.
NAb.
No
significant
difference
response
was
among
history.
Also,
no
impact
presented
factors
sex,
BMI.
findings
highlight
crucial
public
health
how
strategies
could
be
optimized
effectively
during
post-pandemic.
Drug Discovery Today,
Journal Year:
2024,
Volume and Issue:
29(9), P. 104125 - 104125
Published: Aug. 2, 2024
Influenza
still
poses
a
significant
challenge
due
to
its
high
mutation
rates
and
the
low
effectiveness
of
traditional
vaccines.
At
present,
antibodies
that
neutralize
highly
variable
hemagglutinin
antigen
are
major
driver
observed
protection.
To
decipher
how
influenza
vaccines
can
be
improved,
an
analysis
licensed
vaccine
platforms
was
conducted,
contrasting
strengths
limitations
their
different
mechanisms
Through
this
review,
it
is
evident
these
do
not
elicit
robust
cellular
immune
response
critical
for
protecting
high-risk
groups.
Emerging
platforms,
such
as
RNA
vaccines,
induce
responses
may
additive
recognized
mechanism
protection
through
inhibition
overcome
constraints
provide
broader,
protective
immunity.
By
combining
both
humoral
responses,
could
help
guide
future
development.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 11, 2024
Abstract
The
ongoing
evolution
of
SARS-CoV-2,
particularly
through
the
emergence
new
variants,
continues
to
challenge
our
understanding
immune
protection.
While
antibody
levels
correlate
with
protection
against
earlier
variants
like
Alpha
and
Delta,
their
relationship
Omicron
sub-variants
remains
unclear.
To
investigate
role
neutralizing
activity
in
preventing
breakthrough
infections,
we
analyzed
longitudinal
SARS-CoV-2
humoral
responses
ancestral
virus
major
emerging
a
well-characterized
cohort
healthcare
workers
Spain
(N
=
405).
We
found
that
neutralization
titers
are
key
indicators
including
BQ.1
XBB
variants.
Higher
IgG
IgA
were
associated
over
three
6-month
follow-up
periods
sequentially
dominated
by
BA.1,
BA.2,
BA.5,
BQ.1,
sub-variants,
although
strength
association
between
declined
time.
Our
findings
demonstrate
binding
valid
more
evasive
this
Additionally,
results
underscore
importance
continuous
monitoring
updating
vaccination
strategies
maintain
effective
